MIRA
$1.17
MIRA Pharmaceuticals, Inc.
Recent News
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Aurora Cannabis Announced Refocused Strategy as Global Medical Sales Hit Record High in 2026 Third Quarter Canopy Growth Reported Mixed Results in its Fiscal Third Quarter of 2026 Cronos Group Launched Premium Lord Jones Brand in Israel in Global Expansion Push Key Takeaways; Psychedelic Sector Clearmind Announced the Inclusion of its […]
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks fell late Thursday afternoon with the NYSE Health Care Index down 0.2% and the He
Top Premarket Gainers
FiEE (MINM) shares were up 37% in recent Thursday premarket activity, after the company said Wednesd
EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) on Monday revealed new animal study results from SKNY-1, a next-generation oral therapeutic. The company says the findings further support the advancement of SKNY-1 toward Investigational New Drug (IND) enabling studies. With obesity and smoking representing two of the leading causes of preventable death and a combined global market opportunity exceeding $200 billion, MIRA intends to prioritize SKNY-1 as a potential cornerstone asset pending the completio
Psychedelic: Compass, GH Research, MindMed report quarterly earnings
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a patent grant and study results. Q1 EARNINGS: On Thursday, Compass Pathways (CMPS) reported a first quarter loss per share of (24c), which compared to analyst estimates of a loss per share of (49c). The company said cash and cash equivalents were $260.1M as of March 31, compared with $165.1M as of December 31. Compass also guided to full year 2025 net cash used in operatin